Vor Biopharma (VOR) Retained Earnings (2020 - 2026)

Vor Biopharma (VOR) has reported Retained Earnings for 7 consecutive years, with -$1.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 180.42% year-over-year to -$1.4 billion; the TTM figure through Mar 2026 stood at -$1.4 billion (down 180.42% YoY), while the FY2025 annual figure was $41000.0, up 86.36% from the prior year.
• Retained Earnings slipped to -$1.4 billion in Q1 2026 per VOR's latest filing, from $41000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $41000.0 in Q4 2025 and bottomed at -$2.9 billion in Q3 2025.
• Historically, Retained Earnings has averaged -$522.4 million across 5 years, with a median of -$222.2 million in 2022.
• Annual changes were most pronounced in 2024 — Retained Earnings soared 100.01% — and 2025, when it slumped 2947185.71%.
• Vor Biopharma's Retained Earnings stood at -$222.2 million in 2022, then slumped by 53.04% to -$340.1 million in 2023, then jumped by 100.01% to $22000.0 in 2024, then jumped by 86.36% to $41000.0 in 2025, then plunged by 3347904.88% to -$1.4 billion in 2026.
• Business Quant data shows VOR's Retained Earnings at -$1.4 billion in Q1 2026, $41000.0 in Q4 2025, and -$2.9 billion in Q3 2025.